631 related articles for article (PubMed ID: 22716185)
1. Psoriasis: rationale for targeting interleukin-17.
Girolomoni G; Mrowietz U; Paul C
Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy.
Gisondi P; Dalle Vedove C; Girolomoni G
Dermatol Ther (Heidelb); 2014 Jun; 4(1):1-9. PubMed ID: 24452484
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
Kirkham BW; Kavanaugh A; Reich K
Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic implications of IL-17A blockade in psoriasis.
Puig L; Carrascosa JM
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
[No Abstract] [Full Text] [Related]
7. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
8. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
11. [Interleukin-17 as a therapeutic target in psoriasis].
Torres T; Filipe P
Acta Med Port; 2014; 27(2):252-8. PubMed ID: 24813495
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17A and Keratinocytes in Psoriasis.
Furue M; Furue K; Tsuji G; Nakahara T
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070069
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
14. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
15. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-17 and innate immunity in infections and chronic inflammation.
Isailovic N; Daigo K; Mantovani A; Selmi C
J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
[TBL] [Abstract][Full Text] [Related]
17. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
18. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
19. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K; Papp KA; Matheson RT; Tu JH; Bissonnette R; Bourcier M; Gratton D; Kunynetz RA; Poulin Y; Rosoph LA; Stingl G; Bauer WM; Salter JM; Falk TM; Blödorn-Schlicht NA; Hueber W; Sommer U; Schumacher MM; Peters T; Kriehuber E; Lee DM; Wieczorek GA; Kolbinger F; Bleul CC
Exp Dermatol; 2015 Jul; 24(7):529-35. PubMed ID: 25828362
[TBL] [Abstract][Full Text] [Related]
20. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]